首页> 外文OA文献 >Limitations and practical procedure in BclII-Ig heavy chain gene rearrangement real-time quantitative polymerase chain reaction.
【2h】

Limitations and practical procedure in BclII-Ig heavy chain gene rearrangement real-time quantitative polymerase chain reaction.

机译:BclII-Ig重链基因重排实时定量聚合酶链反应的局限性和实用程序。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Follicular lymphoma is characterized by the t(14;18)(q32;q21) translocation, which juxtaposes Ig heavy chain gene (IgH) sequences with the BclII gene. Several publications have highlighted the importance of molecular follow-up in follicular lymphoma, demonstrating that the detection of cells bearing the BclII-IgH rearrangement by real-time quantitative polymerase chain reaction (RQ-PCR) can anticipate a clinical relapse. In this context, we developed a BclII-IgH RQ-PCR. We began with SYBR Green I detection technology but observed that this system does not allow an accurate measurement of the tumor load when working with genomic DNA. While we were designing the assay using Taqman technology, Moppett et al (Moppett J, van der Velden VHJ, Wijkhuijs AJM, Hancock J, van Dongen JJM, Goulden N: Inhibition affecting RQ-PCR-based assessment of minimal residual disease in acute lymphoblastic leukemia: reversal by addition of bovine serum albumin. Leukemia 2003, 17:268-270) reported PCR inhibition problems in around 15% of blood and bone marrow samples, affecting the DNA quantification and thus the assessment of minimal residual disease. They demonstrated that this PCR inhibition could be partially resolved by adding nonacetylated bovine serum albumin. In our studies, we observed the same phenomenon in a single follicular lymphoma case and extended our study to other available cases. As a result, we suggest a new RQ-PCR procedure that is based on Taqman probe technology and that takes into account the PCR inhibition problems, making this assay more reliable in a routine molecular laboratory.
机译:滤泡性淋巴瘤的特征是t(14; 18)(q32; q21)易位,该易位将Ig重链基因(IgH)序列与BclII基因并列。几篇出版物强调了在滤泡性淋巴瘤中进行分子随访的重要性,表明通过实时定量聚合酶链反应(RQ-PCR)检测带有BclII-IgH重排的细胞可以预见临床复发。在这种情况下,我们开发了BclII-IgH RQ-PCR。我们从SYBR Green I检测技术开始,但观察到该系统在使用基因组DNA时无法准确测量肿瘤负荷。当我们使用Taqman技术设计测定方法时,Moppett等人(Moppett J,van der Velden VHJ,Wijkhuijs AJM,Hancock J,van Dongen JJM,Goulden N:抑制作用会影响基于RQ-PCR的急性淋巴细胞白血病最小残留病评估白血病:通过添加牛血清白蛋白来逆转(Leukemia 2003,17:268-270)报告了大约15%的血液和骨髓样本中存在PCR抑制问题,影响DNA定量,从而影响最小残留病的评估。他们证明,通过添加未乙酰化的牛血清白蛋白可以部分解决这种PCR抑制作用。在我们的研究中,我们在单个滤泡性淋巴瘤病例中观察到了相同的现象,并将研究扩展到其他可用病例。结果,我们建议一种新的RQ-PCR程序,该程序基于Taqman探针技术,并考虑到了PCR抑制问题,从而使该测定法在常规分子实验室中更加可靠。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号